TY  - JOUR
A1  - Goßmann, Matthias
A1  - Frotscher, Ralf
A1  - Linder, Peter
A1  - Bayer, Robin
A1  - Epple, U.
A1  - Staat, Manfred
A1  - Temiz Artmann, Aysegül
A1  - Artmann, Gerhard
T1  - Mechano-pharmacological characterization of cardiomyocytes derived from human induced pluripotent stem cells
JF  - Cellular physiology and biochemistry
N2  - Background/Aims: Common systems for the quantification of cellular contraction rely on animal-based models, complex experimental setups or indirect approaches. The herein presented CellDrum technology for testing mechanical tension of cellular monolayers and thin tissue constructs has the potential to scale-up mechanical testing towards medium-throughput analyses. Using hiPS-Cardiac Myocytes (hiPS-CMs) it represents a new perspective of drug testing and brings us closer to personalized drug medication. Methods: In the present study, monolayers of self-beating hiPS-CMs were grown on ultra-thin circular silicone membranes and deflect under the weight of the culture medium. Rhythmic contractions of the hiPS-CMs induced variations of the membrane deflection. The recorded contraction-relaxation-cycles were analyzed with respect to their amplitudes, durations, time integrals and frequencies. Besides unstimulated force and tensile stress, we investigated the effects of agonists and antagonists acting on Ca²⁺ channels (S-Bay K8644/verapamil) and Na⁺ channels (veratridine/lidocaine). Results: The measured data and simulations for pharmacologically unstimulated contraction resembled findings in native human heart tissue, while the pharmacological dose-response curves were highly accurate and consistent with reference data. Conclusion: We conclude that the combination of the CellDrum with hiPS-CMs offers a fast, facile and precise system for pharmacological, toxicological studies and offers new preclinical basic research potential.
KW  - Inotropic compounds
KW  - Pharmacology
KW  - Ion channels
KW  - CellDrum
KW  - Heart tissue culture
KW  - Induced pluripotent stem cells
KW  - Cardiac myocytes
Y1  - 2016
U6  - http://dx.doi.org/10.1159/000443124
SN  - 1421-9778 (Online)
SN  - 1015-8987 (Print)
VL  - 38
IS  - 3
SP  - 1182
EP  - 1198
PB  - Karger
CY  - Basel
ER  - 
TY  - CHAP
A1  - Hunker, Jan
A1  - Jung, Alexander
A1  - Goßmann, Matthias
A1  - Linder, Peter
A1  - Staat, Manfred
ED  - Staat, Manfred
ED  - Erni, Daniel
T1  - Development of a tool to analyze the conduction speed in microelectrode array measurements of cardiac tissue
T2  - 3rd YRA MedTech Symposium 2019 : May 24 / 2019 / FH Aachen
N2  - The discovery of human induced pluripotent stem cells reprogrammed from somatic cells [1] and their ability to differentiate into cardiomyocytes (hiPSC-CMs) has provided a robust platform for drug screening [2]. Drug screenings are essential in the development of new components, particularly for evaluating the potential of drugs to induce life-threatening pro-arrhythmias. Between 1988 and 2009, 14 drugs have been removed from the market for this reason [3]. The microelectrode array (MEA) technique is a robust tool for drug screening as it detects the field potentials (FPs) for the entire cell culture. Furthermore, the propagation of the field potential can be examined on an electrode basis. To analyze MEA measurements in detail, we have developed an open-source tool.
Y1  - 2019
SN  - 978-3-940402-22-6
U6  - http://dx.doi.org/10.17185/duepublico/48750
SP  - 7
EP  - 8
PB  - Universität Duisburg-Essen
CY  - Duisburg
ER  - 
TY  - RPRT
A1  - Stölzle-Feix, Sonja
A1  - Thomas, Ulrich
A1  - Engelstädter, Max
A1  - Goßmann, Matthias
A1  - Linder, Peter
A1  - Staat, Manfred
A1  - Raman, Aravind Hariharan
A1  - Jung, Alexander
A1  - Fertig, Niels
T1  - Plattformtechnologie für kardiale Sicherheitspharmakologie basierend auf teilsynthetischem Herzmuskelgewebe (FLEXcyte) : gemeinsamer FuE-Abschlussbericht aller Partner des Verbundprojektes : Projektlaufzeit: 01.10.2018 bis 30.09.2020
Y1  - 2021
U6  - http://dx.doi.org/10.2314/KXP:1813208581
N1  - Förderkennzeichen BMBF 02P18K020-021
Verbundnummer 01185221
PB  - Nanion Technologies GmbH
CY  - München
ER  -